The effect of sorafenib, bevacizumab and their combination on the relative gene expression of VEGFR2 in HepG2 cancer cells are shown in Fig. 7; all treatments resulted in a significant decrease in the relative expression of VEGFR2 ranging from 0.8 to 0.4 fold (Fig. 7). This evidence concerns the gene KDR and cancer.